

Literaturverzeichnis

zum Titelthema „Prävention in der Frauenheilkunde; Was ist gesichert – was ist Mythos?“

Bayerisches Ärzteblatt 4/2013, Seite 144 f.

von Professor Dr. Birgit Seelbach-Göbel

1. www.bmg.de
2. Donovan B et al: Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. *Lancet Infect Dis*, 2011 Jan; 11 (1):39-44
3. Gøtsche PC, Nielsen M: Screening for breast cancer with mammography. *Cochrane Database Syst Rev*. 2011 Jan 19; (1): CD001877
4. Hofvind S, Lee CI, Elmore JG: Stage-specific breast cancer incidence rates among participants and non-participants of a population-based mammographic screening Programm. *Breast Cancer Res Treat.*, 2012 Aug; 135 (1):291-9
5. Bleyer A, Welch HG: Effect of three decades of screening mammography on breast-cancer incidence. *N Engl J Med*; 2012 Nov 22; 367(21): 1998-2005
6. Marmot MG et al: The benefits and harms of breast cancer screening: an independent review. *Lancet*. 2012 Nov 17; 380(9855):1778-86
7. Buys et al: Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. *JAMA* 2011 Jun 8;305(22):2295-303
8. Schnell-Inderst et al: Individual health services. *GMS Health Technol Assess*.2011;7:Doc05
9. Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Juli 2012, AWMF- Register-Nummer: 032-045OL
10. Burges A, Schmalefeldt B: Ovariakarzinom: Diagnostik und Therapie. *Dtsch. Ärzteblatt Int*.2011; 108(38): 635-41
11. Cuzick J, Powles T, Veronesi U, Forbe J, Edwards R, Ashley s, Boyle P: Overview of the main outcomes in breast-cancer prevention trials. *Lancet*. 2003 Jan 25; 361(9345):296-300
12. Vogel V G et al: Effects of Tamoxifen vs Raloxifene on the Risk of Developing invasive Breast Cancer and Other Disease Outcomes. The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. *JAMA*. June 21, 2006- Vol 295, No. 23
13. Goss PE, Ingle JN, Alés-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al: Exemestane for breast cancer prevention in postmenopausal women. *N Engl J Med* 2011; 364:2381-91
14. Uray IP, Brown PH: Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. *Recent Results Cancer Res*. 2011; 188: 147-62
15. Hung HC et al: Fruit and Vegetable Intake and Risk of Major Chronic Disease. *Journal of the National Cancer Institute*, Vol. 96, No.21, November 3, 2004
16. Van Gils CH et al: Consumption of vegetables and fruits and risk of breast cancer. *JAMA* 2005 Jan 12;293(2):183-93
17. Schulz M et al: Fruit and vegetable consumption and risk of epithelial ovarian cancer: the European Prospective Investigation into Cancer and Nutrition. *Cancer Epidemiol Biomarkers Prev*. 2005 Nov; 14(11 Pt 1):2531-5
18. Bjelakovic G, Nikolova D, Gluud L, Simonetti R G, Gluud C,: Mortality in Randomized trials of Antioxidant Supplements for Primary and Secondary Prevention. Systematic Review ND Meta-analysis. *JAMA*, 2007; 297(8): 842-857
19. Klein E et al: Vitamin E and the Risk Prostate Cancer. The Selenium and Vitamin E Cancer Prevention Trial (SELECT)
20. Dennert G, Zwahlen M, Brinkman M, Vinceti M, Zeegers MP, Horneber M: Selenium for preventing cancer. *Cochrane Database Syst Rev*. 2011 May 11; (5): CD005195
21. Lin J et al: Vitamins E and E and Beta Carotene Supplementation and Cancer Risk: A Randomized Controlled Trial. *J Natl Cancer Inst*. 2009 Jan 7; 101 (1): 14-23
22. Hercberg S et al: Incidence of cancers, ischemic cardiovascular diseases and mortality during 5-year follow-up after stopping antioxidant vitamins and minerals supplements: a postintervention follow-up in the SU.VI.MAX Study. *International Journal of Cancer*: 127, 1875-1881 (2012)
23. Andreeva V et al: B Vitamin and /or ω -3 Fatty Acid Supplementation and Cancer. Ancillary Findings From the Supplementation With Folate, Vitamins B₆ and B₁₂ and/or

Literaturverzeichnis

zum Titelthema „Prävention in der Frauenheilkunde; Was ist gesichert – was ist Mythos?“

Bayerisches Ärzteblatt 4/2013, Seite 144 f.

von Professor Dr. Birgit Seelbach-Göbel

- Omega- 3 Fatty Acids (SU. FOL. OM3) Randomized Trial. Arch Intern Med. 2012 Apr 9; 172(7): 540-7
24. Helzlsouer K for the VDPP Steering Committee: Overview of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. American Journal of Epidemiology. June 18, 2010. Vol. 172, No.1
 25. Garland CF et al: Vitamin D and prevention of breast cancer: Pooled analysis. The Journal of Steroid Biochemistry & Molecular Biology. Journal of Steroid Biochemistry & Molecular Biology 103 (2007) 708-711
 26. Abbas S et al: Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer- results of a large case-control study. Carcinogenesis vol.29 no. 1 pp.93-99, 2008
 27. Bilinski K, Boyages J: Association between 25-hydroxyvitamin D concentration and breast cancer risk in an Australian population: an observational case-control study. Breast Cancer Res Treat. 2013 Jan; 137 (2):559-607
 28. Autier P, Gandini S: Vitamin D Supplementation and Total Mortality. Arch Intern Med. Vol 167 No.16, Sep 10, 2007
 29. Lappe J, Travers-Gustafson D, Davies K, Recker R, Heaney R: Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007; 85:1586-91
 30. Chlebowski R et al: Health Initiative Investigators: Calcium Plus Vitamin D Supplements and the Risk of Breast Cancer. J Natl Cancer Inst, 2007; 100: 1581-1591
 31. Zeeb H, Greinert R: Bedeutung von Vitamin D in der Krebsprävention. Dtsch Ärztebl Int. 2010; 107(37):638-43
 32. Deutsche Gesellschaft für Gynäkologie und Geburtshilfe: Interdisziplinäre S 3-Leitlinie-AWMF 015/062. Stand September 2009
 33. Levis S et al: Soy Isoflavones in the Prevention of Menopausal Bone Loss and Menopausal Symptoms. A Randomized, Double-blind trial. Arch Intern Med/Vol 171 (No.15), Aug 8/22 2011
 34. Yamamoto S, Sobue T, Kobayashi M, Sasaki S, Tsugane S; Japan Public Health Center-Based Prospective Study on Cancer Cardiovascular Diseases Group: Soy, isoflavones, and breast cancer risk in Japan. J Natl Cancer Inst. 2003 Jun 18; 95 (12): 906-13
 35. Verheus M, van Gils CH, Keinan-Boker L, Grace PB, Bingham SA, Peeters PH: Plasma phytoestrogens and subsequent breast cancer risk. J Clin Oncol. 2007 Feb 20; 25(&):648-55
 36. Ward HA, Kuhnle GG, Mulligan AA, Lentjes MA, Luben RN, Khaw KT: Breast, colorectal, and prostate cancer risk in the European Prospective investigation into Cancer and Nutrition-Norfolk in relation to phytoestrogen intake derived from an Improved database. Am J Clin Nutr. 2010 Feb; 91(2):440-8
 37. Bandera EV et al: Phytoestrogen consumption and endometrial cancer risk: a population-based case-control study in New Jersey. Cancer Causes Control. 2009 Sep; 20(7):1117-27
 38. Leitzmann M et al: Prospective study of physical activity and risk of menopausal breast cancer. Breast Cancer Research 2008, 10:R92, published: 31 October 2008